K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
about
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValuePredictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for p53, K-ras and EGFR alterations.Do all lung adenocarcinomas follow a stepwise progression?Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasKRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung.The relationship between aberrant methylation and survival in non-small-cell lung cancers.Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinibMolecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Activation of MEK1/2-ERK1/2 signaling during NNK-induced lung carcinogenesis in female A/J mice.Impact of smoking status on the biological behavior of lung cancer.Role of DMP1 and its future in lung cancer diagnostics.Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clampingDeterminants of survival in advanced non--small-cell lung cancer in the era of targeted therapiesType I insulin-like growth factor receptor induces pulmonary tumorigenesis.Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung.TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis.Molecular changes in smoking-related lung cancer.Selumetinib for the treatment of non-small cell lung cancer.Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer.Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma.The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.p53 and angiogenesis in non-small-cell lung cancer: Reply to the letter from Giatromanolaki and Koukourakis.Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma.Pulmonary adenocarcinoma: classification and molecular biology.Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value.Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung.miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.Effects of the expectorant drug ambroxol hydrochloride on chemically induced lung inflammatory and neoplastic lesions in rodents
P2860
Q24650902-60A6B731-6B67-4091-B222-784185A02025Q26829425-6DE80B84-48E3-492F-AA4F-9660E8B7C413Q33583984-C5D5A500-EDAE-44CD-95F8-263D12657DC3Q35211197-A00E728E-7DCD-4561-86E6-F081BE5D24CBQ35775729-58EE795E-D2D1-4AED-AFBE-43A3F4B4BF13Q36451726-E47D2843-58AB-4E78-9492-B14CB4C9A562Q36621070-46E777B4-C8D6-4B76-A8BF-3CE4AD1ED3DEQ36626149-68795355-E188-44CF-B1FD-97B9C63349D7Q36728450-577FF1FC-A143-41BB-BD7F-AA4A7F448408Q36772562-1E2A628E-7925-4090-AC71-04F0FA8C5FCAQ36895110-7B6FDF3D-9ECB-4441-A054-C02A15200252Q36916714-3D6E12E6-C130-4808-BE3A-877B7AFCA94BQ37111920-4A24BF36-4ED3-4E45-B043-508592C11756Q37141952-40D02C2E-6595-48CC-BDC1-2A5A3866972CQ37146779-899F1D16-BDE9-4D73-ADAC-34592C810486Q37229930-3C13DF65-AED8-4DB7-A142-D95D85EC49F5Q37378176-95707151-627A-46E5-AFF1-C9A2E31C3C24Q37581666-DC0F212D-9DF4-44AF-A1AA-097FC4D74E4DQ37963519-52E39767-3718-4D28-9B96-13AA4557B35FQ38663069-BC033B66-EF6F-45C8-A03C-8A03F4793E85Q39785984-A198C049-59A5-435F-9FBC-A03517723BE1Q40648657-247675CC-E4D3-4B2E-989D-54C2759F2401Q43431016-C6CE3FD2-9A34-4D3F-B582-389C786F5A18Q43463157-901B0AB7-E1AC-48DA-B9C5-D402E207E41AQ44069647-B3FD8D77-92E8-4ED4-9CE5-D0E9E1DA564AQ44499462-73799DF7-599C-4263-8392-C1F4B51DC59AQ46698755-2214B7E3-41D3-467C-9226-E209C634BA30Q47791327-AFEE9D1C-3766-4D10-98A1-05FD720490BDQ48769234-5EF6B9C4-51F5-4677-9D52-8879ADD394A9Q50863745-E38214DE-CB1C-4545-8211-7C9B02681D66Q51051494-1D8A1481-27F5-4CCA-AF59-43DCCC9BF213Q52545817-9460C87B-576D-4FC3-B198-76EF7371317FQ53306726-6F42E3F9-3B90-4F63-A5E0-C09EDDB79C97Q54673900-F57A7066-736E-4BB6-981A-4CF36906EBF3Q54794454-7429C6D8-E3C2-4A69-B5DF-586CAEC06D49Q58596286-27366AF6-1B07-4D45-89EE-A6D6D3AFE9EB
P2860
K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
K-ras and p53 mutations are an ...... th non-small-cell lung cancer.
@ast
K-ras and p53 mutations are an ...... th non-small-cell lung cancer.
@en
type
label
K-ras and p53 mutations are an ...... th non-small-cell lung cancer.
@ast
K-ras and p53 mutations are an ...... th non-small-cell lung cancer.
@en
prefLabel
K-ras and p53 mutations are an ...... th non-small-cell lung cancer.
@ast
K-ras and p53 mutations are an ...... th non-small-cell lung cancer.
@en
P2093
P2860
P356
P1476
K-ras and p53 mutations are an ...... th non-small-cell lung cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1997.194
P407
P577
1997-01-01T00:00:00Z
P5875
P6179
1004112136